Emedgene uses AI to automatically interpret genetic tests, so that health organizations can scale personalized care to wider populations.
Emedgene has raised €5.2M across 1 funding round from 1 investor, most recently a Series A round in Jan 2019. Based in Mazor, Israel; founded 2015; active in Healthtech. Data as of 7 Aug 2026.
Timing: dormant vs cohort gap · momentum unknown. Funding-only estimates, not predictions and not investment advice — see signals.
| Date | Stage | Amount | Investors | |
|---|---|---|---|---|
| 2019-01-01 | Series A | €5.2M |
| Olive Tree Ventures |
| View deal → |
